Evidence map›Paper›PMID 39460388›Full record

ArticleBiotechnology and bioengineering2025

Inhibition Control by Continuous Extractive Fermentation Enhances De Novo 2-Phenylethanol Production by Yeast.

Alessandro Brewster, Arjan Oudshoorn, Marion van Lotringen, Pieter Nelisse, Emily van den Berg, Marijke Luttik, Jean-Marc Daran

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. EngineeringFrontiers in microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alessandro BrewsterDAB.bio, Alexander Fleminglaan 1, Delft, The Netherlands.
Arjan OudshoornDAB.bio, Alexander Fleminglaan 1, Delft, The Netherlands.
Marion van LotringenDAB.bio, Alexander Fleminglaan 1, Delft, The Netherlands.
Pieter NelisseDAB.bio, Alexander Fleminglaan 1, Delft, The Netherlands.
Emily van den BergDAB.bio, Alexander Fleminglaan 1, Delft, The Netherlands.
Marijke LuttikDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.
Jean-Marc DaranDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.ORCID 0000-0003-3136-8193

Funding

This study was supported by European Union's Horizon 2020 research and innovation program under grant agreement No. 720824.
6 · The paper itself

Abstract

Current microbial cell factory methods for producing chemicals from renewable resources primarily rely on (fed-)batch production systems, leading to the accumulation of the desired product. Industrially relevant chemicals like 2-phenylethanol (2PE), a flavor and fragrance compound, can exhibit toxicity at low concentrations, inhibit the host activity, and negatively impact titer, rate, and yield. Batch liquid-liquid (L-L) In Situ Product Removal (ISPR) was employed to mitigate inhibition effects, but was not found sufficient for industrial-scale application. Here, we demonstrated that continuous selective L-L ISPR provides the solution for maintaining the productivity of de novo produced 2PE at an industrial pilot scale. A unique bioreactor concept called "Fermentation Accelerated by Separation Technology" (FAST) utilizes hydrostatic pressure differences to separate aqueous- and extractant streams within one unit operation, where both production and product extraction take place - allowing for the control of the concentration of the inhibiting compound. Controlled aqueous 2PE levels (0.43 ± 0.02 g kg

Indexed as

BioreactorsFermentationPhenylethyl AlcoholSaccharomyces cerevisiaePhenylethyl Alcohol2‐phenylethanolfermentation processflavorin situ product removalproduct inhibitionSaccharomyces cerevisiae

Identifiers

PMID39460388
PMCPMC11718435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.